Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Association between iridocyclitis and immune-related disease: A 2-sample Mendelian randomization study.
Medicine (Baltimore)
November 2024
Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Ophthalmology and Visual Science Key Lab, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Capital Medical University, Beijing, China.
The genetic basis of iridocyclitis, an inflammatory eye disease, remains poorly understood, particularly in relation to autoimmune diseases. This study aimed to explore the causal associations between 6 immune-related diseases and iridocyclitis using Mendelian randomization (MR). A total of 230 single nucleotide polymorphisms (SNPs) significantly associated with systemic lupus erythematosus, ankylosing spondylitis (AS), rheumatoid arthritis (RA), Graves disease (GD), Crohn disease (CD), and allergic contact dermatitis were identified based on stringent MR assumptions.
View Article and Find Full Text PDFThe ever ongoing cosmetic quest to change eye colour.
Acta Ophthalmol
November 2024
Department of Ophthalmology, Amsterdam UMC, AMC, Amsterdam, The Netherlands.
Purpose: To provide a historical overview of the various efforts to change eye colour for purely cosmetic reasons, along with the associated potential risks and harms.
Methods: Literature and online search.
Results: Eye drops containing adrenaline were used during World War II on involuntary inmates of concentration camp Auschwitz-Birkenau.
From Ocular Surface to Intraocular Inflammation: Linking Allergic Conjunctivitis and Uveitis in Pediatric Patients.
Indian J Pediatr
January 2025
Department of Allergy, Immunology and Rheumatology, Children's Hospital, China Medical University Hospital, Taichung, Taiwan.
The safety and efficacy of TNF inhibitors in patients with Behçet's disease: Retrospective study from eastern Turkey.
Clin Immunol
July 2024
Division of Rheumatology, Department of Internal Medicine, Van Training and Research Hospital, Van, Turkey.
Article Synopsis
- The study evaluated clinical features and outcomes in severe/refractory Behçet's disease (BD) patients treated with TNF inhibitors (TNF-i) over three years at a referral center in Eastern Turkey.
- Out of 469 BD patients, 80 were treated with TNF-i, with most getting infliximab (IFX) or adalimumab (ADA), showing high retention rates and low instances of serious adverse events.
- The findings suggest TNF-i treatments are both safe and effective for achieving remission in patients with severe BD, with no reported deaths among those receiving these therapies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!